Condition
Platinum Sensitive Ovarian Cancer
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
300%
3 of 1 completed with results
Key Signals
3 with results33% success
Data Visualizations
Phase Distribution
4Total
P 2 (2)
P 3 (1)
P 4 (1)
Trial Status
Terminated2
Completed1
Not Yet Recruiting1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07295132Phase 2Not Yet Recruiting
RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)
NCT01847274Phase 3Completed
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
NCT02978222Phase 2TerminatedPrimary
Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
NCT02035345Phase 4Terminated
Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
Showing all 4 trials